Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bortezomib Sensitization of Recurrent Grade-4 Glioma With Unmethylated MGMT Promoter to Temozolomide Phase 1B/II Study

NCT03643549 is registered in ClinicalTrials.gov with Haukeland University Hospital as lead sponsor.

NCT NCT03643549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03643549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bortezomib Sensitization of Recurrent Grade-4 Glioma With Unmethylated MGMT Promoter to Temozolomide Phase 1B/II Study
Lead sponsor
Haukeland University Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 30, 2018
Completion date
December 31, 2026
Enrollment
63 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma